

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI APPTEC CO., LTD.*
無錫藥明康德新藥開發股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2359)

**COMPLETION OF REPURCHASE AND CANCELLATION
OF PART OF RESTRICTED A SHARES
UNDER THE 2018 A SHARE INCENTIVE PLAN**

Reference is made to the announcements of WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司) (the “**Company**”) dated July 19, 2019 and September 17, 2019, in relation to the repurchase and cancellation of part of the Restricted A Shares under the 2018 A Share Incentive Plan (the “**Announcements**”). Unless otherwise stated, the terms used in this announcement shall have the same meanings as defined in the Announcements.

On September 20, 2019, the repurchase and cancellation of the Repurchased Restricted A Shares have been completed. The issued share capital of the Company has been reduced from 1,638,043,314 Shares (comprising 1,467,529,754 A Shares and 170,513,560 H Shares) to 1,637,704,965 Shares (comprising 1,467,191,405 A Shares and 170,513,560 H Shares).

By order of the Board
WuXi AppTec Co., Ltd.
Dr. Ge Li
Chairman

Hong Kong, September 20, 2019

As of the date of this announcement, the Board of the Company comprises Dr. Ge Li, Mr. Edward Hu, Mr. Xiaozhong Liu, Mr. Zhaohui Zhang and Dr. Ning Zhao as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Dr. Jiangnan Cai, Ms. Yan Liu, Mr. Dai Feng, Dr. Hetong Lou and Mr. Xiaotong Zhang as independent non-executive Directors.

* *For identification purpose only*